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A B S T R A C T
Magnetic resonance spectroscopy (MRS) noninvasively provides information on the concentration of some cerebral
metabolites in vivo. Among those measurable by proton magnetic resonance spectroscopy (1H-MRS), N-acetyl-aspartate
(NAA) is decreased, and myo-inositol (mI) and choline (Cho) levels are increased in patients with Alzheimer’s disease
(AD). Donepezil, an acetylcholinesteraze inhibitor, has proven effect on cognitive symptoms in patients with AD. In previ-
ous studies, treatment response was associated with an increase of NAA and NAA/Cr in the parietal lobe and hippo-
campi. Correlation of longitudinal changes of 1H-MRS detectable metabolites in dorsolateral prefrontal cortex (DLPFC)
with clinically observable changes is a poorly researched topic. The objective of this non-interventional study is to assess
whether changes in 1H-MRS measurable metabolites correlate with clinical outcome after donepezil treatment. Twelve
patients with mild to moderate AD were evaluated during 26 weeks of donepezil treatment. 1H-MRS parameters in
DLPFC were assessed before and after 26 weeks of donepezil treatment. Cognition was assessed with Alzheimer’s Disease
Assessment Scale cognitive subscale (ADAS-Cog). A significant increase in NAA/Cr ratio and significantly lower de-
crease in mI/Cr ratio were found in AD patients with positive treatment response. The results of this study indicate possi-
ble modest donepezil effect on prevention of neuronal functional deterioration in DLPFC which correlates with clinical
outcome and point the use of 1HMRS as technique of help in assessment of drug effect.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative dis-
ease characterized by progressive loss of memory and im-
paired social functioning. AD may additionally present
with different comorbid psychiatric symptoms such as
anxiety, depression and psychosis. The disease mostly af-
fects the population over 65 years of age and is therefore
the most common cause of age-related cognitive decline
and dementia. However, it may appear in the younger in-
dividuals as well. Since the etiology of this disease is still
mostly unknown there is much room for improvement in
the area of diagnosing the disease before the clinical
signs become apparent as well as the improvement in the
treatment of the disease in its early stages.
One of the most commonly used medication for the
treatment of AD is a cholinesterase inhibitor (ChEI),
donepezil, which is used for the treatment of mild to
moderate stages of the disease. The group of ChEI drugs,
which also includes drugs as galantamine and rivastig-
mine (also used for treatment of AD), currently repre-
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sent the only alternative to treatment with N-methyl- D
-aspartate antagonist memantine, used mainly to treat
severe cases of dementia. Although there are some doubts
with regard to donepezil’s (and ChEI’s in general) ef-
ficacy1, most of the studies2 found their effect stabilizing
in terms of general disease progression. Additionally,
donepezil is considered to be the drug with the best
safety profile in the ChEI group1. In assessing both
safety/tolerability as well as efficacy of any such treat-
ment, an objective method should be employed. In every-
day clinical practice as in the clinical studies, the im-
provement or worsening of the disease is usually monitored
with two scales: Mini-Mental Status Exam (MMSE)3 and
the Alzheimer Disease Assessment Scale – cognitive sub-
scale (ADAS-Cog)4. Mentioned scales are used widely and
routinely so there is no need to discuss them further, ex-
cept to say that, like any rating scale, these are suscepti-
ble to certain biases from both rater and the subject5.
Therefore, it is interesting to compare outcome of two
above mentioned scales to the more »objective» method.
For this purpose, we employed 1-H magnetic resonance
spectroscopy (1H MRS). It is an in vivo, non-invasive di-
agnostic procedure that enables the researcher to follow
concentrations (i.e. concentration readings) of brain me-
tabolites in selected brain regions. Method is used to de-
tect and visualize carbon-bound, non-exchangeable pro-
tons in certain spectral regions. The most well-known
metabolites detected include N-acetylaspartate (NAA) as
an indirect expression of the integrity of neurons6,7,
choline (Cho) containing compounds as metabolites in-
volved in phospholipid membrane synthesis and marker
for glial activity, creatine (Cr) including phosphocreatine
as a marker for energy metabolism, and lactate as an in-
dicator for anaerobic glycolysis detected under pathologi-
cal conditions8–11.
In this study we have monitored the concentration of
N- acetyl aspartate (NAA) since its decrease is usually
considered to manifest neuronal loss, decreased neuronal
viability or impaired neuronal function12. Study of Kri-
shnan et al.13 showed that NAA concentrations in sub-
cortical gray, periventricular, cortical and white matter
showed an increasing trend after donepezil treatment
whereas concentration in the placebo group remained
close to baseline values. However, only results from sub-
cortical gray and periventricular matter managed to
reach the significant change from the baseline. Bartha et
al.14 showed a significant decrease in NAA and NAA/
Creatin (Cr) in hippocampus after a four-month done-
pezil treatment in AD patients.
In this study we have monitored the change in con-
centrations of NAA/Cr in dorsolateral prefrontal cortex
in AD patients before and after 26 weeks of treatment
with donepezil. NAA/Cr ratio was chosen since it is con-
sidered to be the most reliable marker of neuronal integ-
rity available15.
Subjects and Methods
All participants in the study were included as a part of
the recruiting procedure for the clinical study determin-
ing long-term effects of Donepezil, a centrally acting re-
versible cholinesterase inhibitor. In an open-label study,
subjects with moderate to severe Alzheimer’s disease re-
ceived 10 mg formulation of Donepezil. Before inclusion
in the study, DSM IV diagnostic criteria were employed
to appropriately differentiate subjects with AD. Subjects
included were those with mild to moderate dementia ac-
cording to their individual Mini Mental State (MMS)
scores. Other criteria included presence of noticeable
cognitive impairment measured for different cognitive
domains. Instruments used to establish such impairment
were: remembrance of the simple stories (immediate and
after a certain period of time), lingual fluency, figure
copying and memory scales. Also assessed were activities
of daily living and clinical dementia rating scale (by using
ADAS-Cog scale).
Following the above mentioned procedures, diagnos-
tic MRI scans were done on a 3T MRI unit, to exclude po-
tential cerebrovascular disease underlying the diagnosed
clinical condition. Providing all of the above tests sug-
gested diagnosis of AD and neuroradiological finding pro-
vided no proof of underlying cerebrovascular disease,
subjects were diagnosed with AD. All subjects gave their
voluntary informed consent, either themselves, or trough
their caregiver, in case when their condition rendered
them incapable of understanding the subject information
sheet. Altogether 12 subjects (7 female and 5 male) were
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Fig. 1. Spectroscopic Volume of Interest (VOI) in the dorsolateral prefrontal cortex.
included in the study. Mean age of the subjects was 71.4
years (SD=7,04).
1-HMR spectroscopy was performed on a Siemens 3 T
machine, using a radiofrequency transmit/receive head
coil suited for cerebral MRI and magnetic resonance
spectroscopy. The spectroscopic volume of interest (VOI)
of 25x25x25 mm was positioned in the right dorsolateral
prefrontal cortical region (Figure 1). The angulation of
the VOI was achieved either directly by appropriate
switching of the magnetic field gradients or by reclining
the subject’s head in an adequate position. Metabolite
signal ratios of NAA and Cr were determined from the
spectra with TE = 272 msec. Appropriate filtering was
applied to improve the signal to-noise ratio and to con-
vert the lines into a Gaussian shape.
Statistical analysis was done in Statistica software
package (Statsoft, Tulsa, OK, USA), version 8. Due to
small sample size, nonparametric methods had to be
used to compare before NAA/Cr ratios before and after
the 26-week treatment. To test the null hypothesis that
there is no difference between the distributions of NAA/
Cr ratios before and after Donepezil treatment was ad-
ministered, i.e. to compare paired samples of ratios, Sign
test was used.
Results
In all 12 subjects NAA and Cr levels were measured in
the DLPFC area using the above mentioned technique
before and after the 26 weeks (95% confidence intervals
were 25,1 and 26,3 weeks) of Donepezil treatment. Mea-
surement results were combined to calculate a NAA/Cr
ratio and are displayed in Figure 2.
We found NAA/Cr ratios to be generally lower at the
baseline visit compared to the visit after the treatment.
This was true for 10 out of 12 subjects studied. Two sub-
jects, Nos. 4 and 8, both females older than 70 years of
age, showed a different pattern with higher NAA/Cr ra-
tios at baseline. However, even in these subjects, a lower
cognitive decline was observed than we expected, a fact
also described by other authors16.
Overall, mean NAA/Cr ratios before Donepezil treat-
ment was administered were 1.39 (SD=0.207; 95% confi-
dence intervals 1.26 and 1.52). After the treatment, mean
ratio was 1.48 (SD=0.241; 95% CIs of 1.32 and 1.63).
Mean difference between the first and the second mea-
surement was thus 0.085 (SD=0.218; 95% CIs of –0.052
and 0.222). Differences between measurements were com-
pared by the appropriate non-parametric test, as de-
scribed before and were found to be statistically signifi-
cant (p=0.043, Z=2.02). The conclusion can be made
that there was statistically significant increase in NAA/
Cr ratios after approximately 6 months of Donepezil
treatment in subjects suffering from mild to moderate
Alzheimer’s disease.
Discussion
Practically all 1H-MRS studies published to date re-
veal lower NAA values in cortical areas of subjects with
AD when compared to healthy people of the appropriate
age17. On the other hand, myoinositol levels are found to
be lower, while choline levels were reported to be both
elevated18 and not elevated19 when such comparisons are
performed. NAA therefore seemed like a logical choice
for neuronal damage assessment in the present study.
Additionally, it is, unlike myoinositol, found exclusively
in the nervous system, where its levels depend on the in-
tensity of oxidative phosphorylation processes in the
neuronal mytochondria. It is quite possible that decrease
in NAA seen by the 1H-MRS could be, at least in the be-
ginning, consequence of mytochondrial dysfunction, ra-
ther than net grey matter neuronal loss. Or, in words of
Krishnan et al.20, NAA concentrations may reflect both
neuronal function and content. Since our premise is that
this function/content discrepancy may not happen at the
same time, there could exist a specific time-point be-
tween the initial, possibly reversible, NAA decrease and
later permanent decrease. This gap in return could (at
least in theory) be the target of the pharmacological in-
tervention by donepezil or any of the other available
treatments. In this context, donepezil is known to in-
crease relative NAA/Cr ratio compared to placebo in the
beginning of the treatment, up to week 621 and possibly
week 1820. We wanted to see what happens with NAA/Cr
ratios after this stage, so we observed subjects for a pe-
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Fig. 2. NAA/Cr ratios for each of 12 subjects studied, before (grey)
and after (black) the 26-weeks treatment with Donepezil.
Fig. 3. Typical NAA/Cr ratios before and after donepezil treat-
ment. Note relatively constant Cr levels as opposed to significant
increase in levels of NAA.
riod of 26 weeks. Typical NAA/Cr ratio observed before
treatment differed significantly from that after treat-
ment (Figure 3).
With relatively constant Cr levels observed on both
visits, NAA levels were elevated significantly after the
treatment period, as mentioned in the Results section.
These results, although derived from the relatively small
number of subjects, suggest that positive effect of such
treatment on NAA levels may be longer lasting that it
was previously thought. While needing more confirma-
tion, these results suggest that similar study, but with
much longer follow-up period is needed to confirm our
results and investigate the possibility of medium- to
long-term effects on donepezil on NAA concentrations.
In combination with previously mentioned finding that
subjects initially described as non-responders could also
benefit from donepezil treatment, a prolonged study of
such type with a higher number of subjects would repre-
sent a welcome addition to current knowledge on this issue.
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1-H MRS PROMJENE U DORZOLATERALNOM PREFRONTALNOM KORTEKSU NAKON PRIMJENE
DONEPEZILA U PACIJENATA S BLAGIM I UMJERENIM OBLICIMA ALZHEMIEROVE BOLESTI
S A @ E T A K
Magnentno rezonantna spektroskopija (MRS) metoda je koja neinvazivno pru`a informacije o in-vivo koncetraciji
odre|enih metabolita u mozgu. Me|u metabolitima koji se mogu mjeriti protonskommagnentno rezonantnom spektro-
skopijom (1H-MRS) u bolesnika s Alzheimerovom bole{}u (AD) sni`ene su razine N-acetil-aspartata (NAA), dok su
razine mio-inozitola (mI) i kolina (Cho) povi{ene. Donepezil, inhibitor enzima acetilkolin esteraze, pokazao se u~inko-
vitim u lije~enju kognitivnih simptoma u bolesnika od AD. U prethodnim ispitivanjima, odgovor na lije~enje bio je
povezan s povi{enim vrijednostima NAA i omjera NAA/Cr u parijetalnom re`nju i hipokampusu. Ipak, povezanost pro-
mjene vrijednosti metabolita koji se mogu otkriti metodom 1H-MRS u podru~ju dorzolateralnog prefrontalnog korteksa
(DLPFC) s klini~ki uo~ljivim promjenama slabo je istra`eno podru~je. Cilj ovog neinterventnog ispitivanja je procijeniti
da li promjene u metabolitima koji se mogu otkriti metodom 1H-MRS odgovara klini~kom rezultatu nakon lije~enja
donepezilom. Promatrano je 12 ispitanika s blagom do umjerenom AD tijekom 26 tjedana lije~enja donepezilom. Para-
metri mjereni metodom 1H-MRS ispitani su prije i nakon 26-tjednog lije~enja donepezilom. Kori{tena je i ljestvica »Alz-
heimer’s Disease Assessment Scale cognitive subscale« (ADAS-Cog) za procjenu mentalnog stanja ispitanika. Znatno
pove}anje omjera NAA/Cr i znatno manje sni`enje omjera mI/Cr prona|eni su u bolesnika s pozitivnim odgovorom na
lije~enje. Rezultati ovog ispitivanja upu}uju na mogu}e blago pozitivne u~inke donepezila na usporavanje funkcional-
nog propadanja neurona u podru~ju DLPFC. Tako|er, metoda 1H-MRS pokazala se korisnom u procjeni u~inaka lijeka.
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